KR101244101B1 - Cosmetic composition for improving skin inflammation and including a fermented product of paprika as an effective ingredient - Google Patents
Cosmetic composition for improving skin inflammation and including a fermented product of paprika as an effective ingredient Download PDFInfo
- Publication number
- KR101244101B1 KR101244101B1 KR1020100098353A KR20100098353A KR101244101B1 KR 101244101 B1 KR101244101 B1 KR 101244101B1 KR 1020100098353 A KR1020100098353 A KR 1020100098353A KR 20100098353 A KR20100098353 A KR 20100098353A KR 101244101 B1 KR101244101 B1 KR 101244101B1
- Authority
- KR
- South Korea
- Prior art keywords
- paprika
- cosmetic composition
- skin inflammation
- improving skin
- inflammation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 title claims abstract description 78
- 239000001511 capsicum annuum Substances 0.000 title claims abstract description 67
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 239000002537 cosmetic Substances 0.000 title claims abstract description 26
- 201000004624 Dermatitis Diseases 0.000 title claims abstract description 18
- 240000008384 Capsicum annuum var. annuum Species 0.000 title abstract description 59
- 239000004615 ingredient Substances 0.000 title description 5
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims abstract description 19
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims abstract description 19
- 102000003820 Lipoxygenases Human genes 0.000 claims abstract description 15
- 108090000128 Lipoxygenases Proteins 0.000 claims abstract description 15
- 206010061218 Inflammation Diseases 0.000 claims abstract description 11
- 230000004054 inflammatory process Effects 0.000 claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 102000003945 NF-kappa B Human genes 0.000 claims abstract 2
- 108010057466 NF-kappa B Proteins 0.000 claims abstract 2
- 240000004160 Capsicum annuum Species 0.000 claims description 23
- 239000006071 cream Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 9
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 239000006210 lotion Substances 0.000 claims description 7
- 235000016709 nutrition Nutrition 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 4
- 230000035764 nutrition Effects 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 3
- -1 pack Substances 0.000 claims description 3
- 235000012658 paprika extract Nutrition 0.000 claims description 3
- 239000001688 paprika extract Substances 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 2
- 230000003020 moisturizing effect Effects 0.000 claims description 2
- 239000002453 shampoo Substances 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims 1
- 230000001070 adhesive effect Effects 0.000 claims 1
- 230000005732 intercellular adhesion Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- 206010015150 Erythema Diseases 0.000 abstract description 5
- 208000003251 Pruritus Diseases 0.000 abstract description 5
- 231100000321 erythema Toxicity 0.000 abstract description 5
- 230000007803 itching Effects 0.000 abstract description 5
- 238000000855 fermentation Methods 0.000 description 35
- 230000004151 fermentation Effects 0.000 description 35
- 239000000523 sample Substances 0.000 description 20
- 239000013068 control sample Substances 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 8
- 239000000284 extract Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 210000001626 skin fibroblast Anatomy 0.000 description 6
- 235000002567 Capsicum annuum Nutrition 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 235000002566 Capsicum Nutrition 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 229960000905 indomethacin Drugs 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 3
- 229920002498 Beta-glucan Polymers 0.000 description 3
- 240000008574 Capsicum frutescens Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 235000002568 Capsicum frutescens Nutrition 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000001851 biosynthetic effect Effects 0.000 description 2
- 239000001390 capsicum minimum Substances 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 229940113124 polysorbate 60 Drugs 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229950011392 sorbitan stearate Drugs 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- FTZIQBGFCYJWKA-UHFFFAOYSA-N 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 FTZIQBGFCYJWKA-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 235000019510 Long pepper Nutrition 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 241000722363 Piper Species 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 241000758706 Piperaceae Species 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241001247145 Sebastes goodei Species 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 235000005811 Viola adunca Nutrition 0.000 description 1
- 240000009038 Viola odorata Species 0.000 description 1
- 235000013487 Viola odorata Nutrition 0.000 description 1
- 235000002254 Viola papilionacea Nutrition 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229930185472 acuminatum Natural products 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- IAQRGUVFOMOMEM-UHFFFAOYSA-N butene Natural products CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000010335 hydrothermal treatment Methods 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000001875 irritant dermatitis Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/911—Microorganisms using fungi
- Y10S435/94—Saccharomyces
- Y10S435/942—Saccharomyces cerevisiae
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dispersion Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 파프리카 발효물을 유효 성분으로 함유하는 피부 염증 개선용 화장료 조성물에 관한 것으로, 본 발명의 조성물은 피부 염증과 밀접히 관련된 NF-kB, 리폭시게나제 및 ICAM-1 단백질의 발현을 억제하고 홍반, 가려움 등을 억제하여 우수한 염증 개선 효과를 가지며, 인체에 안전하게 사용될 수 있다.The present invention relates to a cosmetic composition for improving skin inflammation containing paprika ferment as an active ingredient, the composition of the present invention inhibits the expression of NF-kB, lipoxygenase and ICAM-1 protein closely related to skin inflammation and erythema By suppressing itching, etc., it has an excellent inflammation improvement effect and can be used safely in the human body.
Description
본 발명은 파프리카 발효물(a fermented product)의 용도, 보다 구체적으로는 파프리카 발효물을 유효 성분으로 포함하는 피부 염증 개선용 화장료 조성물에 관한 것이다.The present invention relates to the use of a paprika fermented product (a fermented product), and more particularly to a cosmetic composition for improving skin inflammation comprising the paprika fermented product as an active ingredient.
피부는 외부 환경에 직접적으로 노출되는 신체 부위로서, 과도한 자외선이나 오염물질 또는 자극원에 노출되면 홍반, 부종, 가려움 등의 피부 자극 및 염증 반응이 유발된다. 이러한 피부 자극 스트레스에 의한 피부 트러블은 미관상 문제가 될 뿐만 아니라, 염증 반응 과정에서 생성되는 물질들이 부수적으로 피부의 색소 침착을 일으키고, 피부 탄력 섬유의 붕괴를 촉진시켜 피부 주름의 증가에까지 영향을 미치는 것으로 알려져 있다(Toxicol In Vitro, 18:231-43 (2004); Irritant dermatitis, 87-111(1996)).The skin is a part of the body that is directly exposed to the external environment. Exposure to excessive ultraviolet rays, pollutants or irritants causes skin irritation and inflammatory reactions such as erythema, edema, and itching. The skin trouble caused by the skin irritation stress is not only aesthetic problem, but also the substances produced during the inflammatory reaction incidentally cause pigmentation of the skin and promote the breakdown of the skin elastic fibers to affect the increase of skin wrinkles. Known (Toxicol In Vitro, 18: 231-43 (2004); Irritant dermatitis, 87-111 (1996)).
현재까지는 상기와 같은 피부 염증의 치료를 위해 주로 항히스타민제, 비타민 연고, 부신피질호르몬제가 사용되고 있으나, 그 효과가 일시적인 경우가 대부분이고 부작용이 심한 경우도 많다.Until now, antihistamines, vitamin ointments, and corticosteroids are mainly used for the treatment of skin inflammation, but the effects are often temporary and often have severe side effects.
화장품의 사용에 의해 일어날 수 있는 피부자극 및 염증 반응으로는 가려움 (itching), 따끔거림 (stinging) 및 화끈거림 (burning)등의 자극감과 홍반 (erythema), 부종 (edema) 등이 있다.Skin irritation and inflammatory reactions that may occur with the use of cosmetics include irritation such as itching, stinging and burning, erythema, and edema.
이러한 피부 자극을 완화하기 위해서 피부 자극 유발 물질을 제거하는 방법 등 다양한 방법이 동원되었으나, 최근에는 기능성 화장품 제조가 늘어나고 있으며, 기능성 원료 자체가 자극원으로 작용하는 경우가 허다하기 때문에 이와 같은 연구는 한계가 있다고 할 수 있다.In order to alleviate the skin irritation, various methods such as removing skin irritants have been mobilized, but in recent years, functional cosmetics manufactures are increasing, and the functional material itself is often used as a stimulus source. It can be said.
이에, 본 발명자들은 화장품에 의한 부작용을 줄이고 인체에 안전하면서 항염 효능이 우수한 물질을 찾기 위하여 여러 가지 천연 식물을 대상으로 연구한 결과, 파프리카 발효물이 피부 염증과 밀접히 관련된 NF-kB, 리폭시게나제 및 ICAM-1 단백질의 발현을 억제함으로써 피부염증의 억제에 탁월한 효과가 있는 것을 확인하고 이를 토대로 본 발명을 완성하였다. Accordingly, the present inventors studied various natural plants in order to reduce side effects caused by cosmetics and to find substances that are safe for humans and have excellent anti-inflammatory effects. As a result, paprika fermented products are closely related to skin inflammation, NF-kB and lipoxygenase. And by inhibiting the expression of ICAM-1 protein confirmed that it has an excellent effect on the inhibition of dermatitis and completed the present invention based on this.
따라서, 본 발명의 목적은 파프리카 발효물을 유효 성분으로 포함하는 피부 염증 개선용 화장료 조성물에 관한 것이다.Accordingly, an object of the present invention relates to a cosmetic composition for improving skin inflammation comprising a paprika fermented product as an active ingredient.
상기 목적에 따라, 본 발명은 파프리카 발효물을 유효 성분으로 포함하는 피부 염증 개선용 화장료 조성물을 제공한다.In accordance with the above object, the present invention provides a cosmetic composition for improving skin inflammation comprising a paprika fermented product as an active ingredient.
본 발명의 파프리카 발효물을 포함하는 파프리카 발효물을 유효 성분으로 포함하는 피부 염증 개선용 화장료 조성물은 피부 염증과 밀접히 관련된 NF-kB, 리폭시게나제 및 ICAM-1 단백질의 발현을 억제하여 우수한 염증 개선 효과를 가지며, 인체에 안전하게 사용될 수 있다.The cosmetic composition for improving skin inflammation comprising the paprika fermentation product including the paprika fermentation product of the present invention as an active ingredient is excellent in improving inflammation by inhibiting the expression of NF-kB, lipoxygenase and ICAM-1 protein closely related to skin inflammation. It has an effect and can be used safely in the human body.
도 1은 인간 피부 섬유아세포에 대한 본 발명의 파프리카 발효물의 세포독성 시험 결과를 보여주는 그래프이다 (Control: 미처리 세포군, C: 파프리카 대조 시료 처리군, FSc: 파프리카 발효 시료 처리군).
도 2는 본 발명의 파프리카 발효물에 의한 리폭시게나제 저해 정도를 보여주는 그래프이다 (Control: 인도메타신 처리군, C: 파프리카 대조 시료 처리군, FSc: 파프리카 발효 시료 처리군).
도 3은 본 발명의 파프리카 발효물에 의한 ICAM-1 단백질의 발현 억제 정도를 보여주는 그래프이다 (No UV control: UV 미처리군, Control: UV 처리군, C: 파프리카 대조 시료 처리군, FSc: 파프리카 발효 시료 처리군).
도 4는 본 발명의 파프리카 발효물에 의한 NF-kB 단백질의 발현 억제 정도를 보여주는 그래프이다 (No UV control: UV 미처리군, Control: UV 처리군, C: 파프리카 대조 시료 처리군, FSc: 파프리카 발효 시료 처리군). 1 is a graph showing the cytotoxicity test results of the paprika fermentation of the present invention on human skin fibroblasts (Control: untreated cell group, C: paprika control sample treatment group, FSc: paprika fermentation sample treatment group).
2 is a graph showing the degree of inhibition of lipoxygenase by the paprika fermentation product of the present invention (Control: indomethacin treatment group, C: paprika control sample treatment group, FSc: paprika fermentation sample treatment group).
Figure 3 is a graph showing the degree of inhibition of expression of ICAM-1 protein by the paprika fermentation of the present invention (No UV control: UV untreated group, Control: UV treated group, C: Paprika control sample treatment group, FSc: Paprika fermentation Sample treatment group).
4 is a graph showing the degree of inhibition of expression of NF-kB protein by the paprika fermentation product of the present invention (No UV control: no UV treatment group, Control: UV treatment group, C: paprika control sample treatment group, FSc: paprika fermentation) Sample treatment group).
NF-kB(Nuclear factor kappa-light-chain-enhancer of activated B cells)는 면역기능, 급성기 반응, 세포주기 조절 등 다양한 세포활동을 조절하는 전사인자로서 외부 자극에 의해 세포질에 존재하던 NF-kB가 핵 속으로 이동되어 여러 유전자의 kB element에 결합, 그 유전자의 전사를 야기한다. NF-kB는 종양의 발병은 물론 면역 활성도 및 염증 반응계에 중요한 영향을 미친다. NF-kB의 자극으로 특정 유전자 발현 속도가 증가하면 관련 효소 및 단백질 생산이 늘어나서 염증성 프로스타글란딘(prostaglandin) 및 기타 에이코사노이드(eicosanoids) 생산을 비정상적으로 증가시킨다. 또한 NF-kB 활성이 증가하면 면역계가 과잉 활성화 되어 다양한 자가 면역 질환 및 염증 반응이 악화된다. NF-kB 자극을 받으면 염증과 암발생에 중요한 원인 단백질인 COX(cylooxygenase)라는 효소의 생성 및 활성이 비정상적으로 증가된다. NF-kB의 주된 활성화 인자는 유리 라디칼(free radical) (예: UV에서 유도된 유리 라디칼)이다 (Arch Dermatol Res, 302:5-17 (2010); The Journal of Clinical Investigation, 107(1): 3-11 (2001)).NF-kB (Nuclear factor kappa-light-chain-enhancer of activated B cells) is a transcription factor that modulates various cellular activities such as immune function, acute phase response, and cell cycle regulation. It moves into the nucleus and binds to kB elements of several genes, causing transcription of that gene. NF-kB has an important effect on the development of tumors as well as on immune activity and the inflammatory response system. Stimulation of NF-kB increases the rate of expression of certain genes, leading to an increase in the production of related enzymes and proteins, which abnormally increases the production of inflammatory prostaglandin and other eicosanoids. Increasing NF-kB activity also overactivates the immune system, exacerbating various autoimmune diseases and inflammatory responses. NF-kB stimulation abnormally increases the production and activity of an enzyme called COX (cylooxygenase), which is an important cause of inflammation and cancer. The main activator of NF-kB is free radicals (eg, free radicals derived from UV) (Arch Dermatol Res, 302: 5-17 (2010); The Journal of Clinical Investigation, 107 (1): 3-11 (2001)).
이외, 리폭시게나제(lipoxygenase)는 각종 염증 및 알러지성 질환의 생합성 반응에 관여하는 효소이고 (Advances in Biological Research 2 (3-4): 56-59 (2008); J. Food Sci. Nutr. 4(3): 163-166 (1999)), ICAM-1(Intercellular adhesion molecule-1)은 혈관내피세포에서 생성되는 단백질로서 염증세포의 체내이동 및 집속에 작용하여 염증반응을 증폭시키는 역할을 한다 (J. Nutr. 134: 1013-1019 (2004); John Wiley & Sons A/S, Experimental Dermatology, 19, e182-e190 (2010)). In addition, lipoxygenase is an enzyme involved in the biosynthetic response of various inflammatory and allergic diseases (Advances in Biological Research 2 (3-4): 56-59 (2008); J. Food Sci. Nutr. 4). (3): 163-166 (1999)), ICAM-1 (Intercellular adhesion molecule-1) is a protein produced by vascular endothelial cells and acts to amplify the inflammatory response by acting on the body's movement and concentration of inflammatory cells ( J. Nutr. 134: 1013-1019 (2004); John Wiley & Sons A / S, Experimental Dermatology, 19, e182-e190 (2010)).
본 발명은 상기 NF-kB, 리폭시게나제 및 ICAM-1 단백질 발현을 억제하고 홍반, 가려움과 같은 염증 관련 증상의 완화에 효과를 발휘할 수 있는 피부 화장료 조성물을 제공한다. 본 발명의 조성물은 파프리카 발효물을 유효 성분으로 함유한다.The present invention provides a skin cosmetic composition capable of inhibiting the expression of the NF-kB, lipoxygenase and ICAM-1 protein and exerting an effect on the relief of inflammation-related symptoms such as erythema and itching. The composition of the present invention contains paprika fermented product as an active ingredient.
파프리카(Capsicum annuum var. angulosum)는 나라에 따라서 Sweet pepper, Bell pepper, Pimemto, Paprika 등으로 불리며 우리나라에서는 착색 단고추로 불리기도 한다. 고추는 Solanaceae과(가지과), Capsicum속(고추속), Annuum종(고추종)으로 분류되고 6개의 아종, 즉, 칠리고추(Chili pepper, Capsicum annuum L. var. acuminatum), 피망(Bell or sweet pepper, Capsicum annuum L. var. grossum), 콘고추(Cone pepper, Capsicum annuum L. var. abbreviatum), 체리고추(Cherry pepper, Capsicum annuum L. var. cerasiforme)), 레드클러스터고추(Red cluster pepper, Capsicuum annum L. var. fasciculatum), 긴고추(Long pepper, Capsicum annuum L. var. longum)이 있으며, 일반적으로 매운고추(Hot pepper)와 단고추(Sweet pepper)로 구분되는데 이 중 파프리카는 단고추에 속한다.Paprika ( Capsicum annuum var. Angulosum is called Sweet Pepper, Bell Pepper, Pimemto, Paprika, etc., depending on the country. Peppers are classified into Solanaceae family, Capsicum genus, Annuum species, and 6 subspecies: Chili pepper, Capsicum annuum L. var. Acuminatum , Bell or sweet pepper, Capsicum annuum L. var. grossum ), Cone pepper, Capsicum annuum L. var. abbreviatum ), Cherry pepper, Capsicum annuum L. var. cerasiforme )), Red cluster pepper, Capsicuum annum L. var. fasciculatum ), Long pepper, Capsicum annuum L. var. longum ), generally divided into hot pepper and sweet pepper, of which paprika belongs to sweet pepper.
본 발명에서 사용된 “파프리카”는 상술한 좁은 개념의 파프리카(Capsicum annuum var. angulosum)뿐만 아니라 6개의 아종을 포함한 고추종(Capsicum annuum)을 포괄하는 개념으로 해석하며, 설명의 편의를 위해 단순히 파프리카(Paprika)로 약칭하도록 한다. The "paprika" used in the present invention bell peppers (Capsicum including six sub-species, as well as paprika (Capsicum annuum var. Angulosum) of a narrow concept described above Annuum ) is interpreted as a comprehensive concept and is simply abbreviated as Paprika for convenience of explanation.
본 발명에 따른 파프리카 발효물은 파프리카 원료 또는 파프리카 원료의 파쇄물 또는 추출물에 효모를 접종한 후 함께 배양함으로써 제조될 수 있다. 구체적인 발효물 제조방법은 본 출원인((주)미애부)에 의해 출원된 대한민국 특허출원 제2010-0055218호를 참조하여 수행될 수 있다. 예를 들면, 파프리카 발효물은 파프리카 원료를 분쇄하여 100 내지 121℃에서 15 내지 30분 동안 열수 처리하고 효모균을 접종한 후 30 내지 37℃, 1 내지 2 vvm 통기량 조건에서 24 내지 72 시간 동안 배양하여 얻어질 수 있다. 이때, 효모균은 1 내지 2%의 양으로 접종하여 사용될 수 있다. 바람직하게는, 파프리카 발효물은, 효모균을 이용한 배양 후, 증류수, 에탄올, 메탄올, 헥산 및 부탄올 중에서 선택된 용매를 이용하여 100 내지 121℃에서 15 내지 30분 동안 추출하고, 여과 및 감압농축한 다음 동결건조하여 사용될 수 있다. 여과, 감압농축 및 동결건조는 천연물 추출에 일반적으로 알려진 방법들이 사용될 수 있다. Paprika fermentation according to the present invention may be prepared by inoculating yeast in paprika raw material or crushed products or extracts of paprika raw material and then cultured together. Specific fermented product manufacturing method may be performed with reference to Korean Patent Application No. 2010-0055218 filed by the present applicant (Miaebu Co., Ltd.). For example, paprika ferment is pulverized paprika raw material for 15 to 30 minutes hydrothermal treatment at 100 to 121 ℃ and incubated for 24 to 72 hours at 30 to 37 ℃, 1 to 2 vvm aeration conditions after inoculation with yeast Can be obtained. At this time, yeast is It can be used by inoculating in an amount of 1 to 2%. Preferably, the paprika fermented product is, after culturing with yeast, extracted for 15 to 30 minutes at 100 to 121 ℃ using a solvent selected from distilled water, ethanol, methanol, hexane and butanol, filtered and concentrated under reduced pressure and then frozen It can be used by drying. Filtration, reduced pressure concentration and lyophilization can be used with methods generally known for natural product extraction.
사용가능한 효모균은 사카로마이세스 속(Saccaromyces sp.) 균주이며, 예를 들면 Saccaromyces cerevisiae 및 Saccharomyces bayanus 중에서 선택될 수 있다. 바람직하게는 본 출원인에 의해 기탁된 Saccharomyces cerevisiae MAB Y1 (기탁번호: KCTC 11386BP)일 수 있다. Usable yeast is Saccaromyces sp .) strain, for example Saccaromyces cerevisiae and Saccharomyces It can be chosen from bayanus . Preferably Saccharomyces cerevisiae MAB Y1 (Accession No .: KCTC 11386BP) deposited by Applicant.
본 발명에서 사용된 “파프리카 발효물”은 발효액 뿐만 아니라, 발효액의 추출물, 또는 이러한 추출물을 여과 및/또는 감압농축한 농축물, 또는 그 농축물을 건조(동결건조)하여 제조한 분말 등의 형태일 수 있다. As used herein, “paprika fermented product” is not only a fermentation broth, but also an extract of a fermentation broth, or a concentrate prepared by filtering and / or depressurizing the extract, or a powder prepared by drying (freeze-drying) the concentrate. Can be.
본 발명의 조성물에서 파프리카 발효물은 조성물의 총 중량을 기준으로 0.1 내지 2 중량%, 바람직하게는 0.5 내지 1 중량%로 함유될 수 있다. 상기 함량 범위를 충족할 경우 상 분리와 같은 제형 안정성에 영향을 미치지 않으면서 홍반, 가려움 등과 같은 염증의 완화에 더 효과적이다.Paprika fermentation in the composition of the present invention may be contained in 0.1 to 2% by weight, preferably 0.5 to 1% by weight based on the total weight of the composition. Meeting the above content range is more effective in alleviating inflammation such as erythema, itching and the like without affecting formulation stability such as phase separation.
본 발명의 화장료 조성물은 다양한 화장품 제형으로 제조될 수 있으며, 예를 들면 유연화장수, 영양화장수, 영양로션, 마사지 크림, 보습 크림, 영양 크림, 팩, 젤, 바디 로션, 바디 크림, 바디 오일, 바디 에센스, 샴푸, 바디클렌저, 입용제 또는 피부점착 타입 화장료로 제형화될 수 있다. 본 발명의 화장료 조성물은 제형 또는 사용 목적에 따라 상기 파프리카 발효물 이외에 화장품의 제조에 통상적으로 사용되는 다른 성분들을 추가로 포함할 수 있다.
The cosmetic composition of the present invention can be prepared in a variety of cosmetic formulations, for example, supple cosmetics, nourishing lotion, nutrition lotion, massage cream, moisturizing cream, nutrition cream, pack, gel, body lotion, body cream, body oil, body It may be formulated as an essence, shampoo, body cleanser, preparation, or skin type cosmetic. The cosmetic composition of the present invention may further include other ingredients conventionally used in the preparation of cosmetics in addition to the paprika fermentation depending on the formulation or purpose of use.
이하, 실시예(examples)를 들어 본 발명을 구체적으로 설명하고 있으나, 이는 단지 본 발명에 대한 이해를 돕기 위한 것으로, 본 발명의 권리범위가 하기 실시예에 한정되는 것은 아니다.
Hereinafter, the present invention will be described in detail with reference to examples. However, this is merely to aid the understanding of the present invention, and the scope of the present invention is not limited to the following examples.
<준비예 1> 파프리카 발효 시료의 준비Preparation Example 1 Preparation of Paprika Fermentation Sample
파프리카(적색 친환경농산물, 경남 진주) 37.5g을 파쇄하여 증류수 62.5 ㎖를 혼합한 후, 배양을 위해 121℃에서 15분간 멸균하였다. 멸균이 끝난 파프리카 분쇄액에 2%의 효모균(Saccharomyces cerevisiae, MAB Y1, KCTC 11386BP)을 접종하여 30℃에서 24시간 동안 배양하였다.37.5 g of paprika (red eco-friendly agricultural product, Gyeongnam Pearl) was crushed to mix 62.5 ml of distilled water, and then sterilized at 121 ° C. for 15 minutes for culture. Saccharomyces 2% in sterile paprika grind cerevisiae , MAB Y1, KCTC 11386BP) were inoculated and incubated at 30 ° C. for 24 hours.
배양 후 얻어진 파프리카 발효액에 50% 에탄올(150 ㎖)을 혼합하고 121℃에서 추출 및 멸균과정을 거친 후 여과하여 80℃에서 1/2로 감압 농축하였다. 농축액을 -70℃에서 무게가 변하지 않을 때까지 동결건조하여 3.1g의 분말(이하, “파프리카 발효 시료”로 언급함)을 얻었다. 50% ethanol (150 mL) was mixed with the paprika fermentation broth obtained after the culture, and extracted and sterilized at 121 ° C., filtered, and concentrated under reduced pressure to 1/2 at 80 ° C. The concentrate was lyophilized at −70 ° C. until its weight did not change to obtain 3.1 g of powder (hereinafter referred to as “paprica fermentation sample”).
효모균을 이용한 발효과정이 생략된 것을 제외하고는 상술한 바와 동일한 과정으로 얻어진 파프리카 추출 분말 시료를 파프리카 발효 시료의 대조 시료로 사용하였다.
A paprika extract powder sample obtained by the same process as described above was used as a control sample of the paprika fermentation sample, except that the fermentation process using the yeast was omitted.
<< 시험예Test Example 1> 세포독성 시험 ( 1> Cytotoxicity Test ( MTTMTT 분석) analysis)
상술한 준비예 1에서 제조한 파프리카 발효 시료 및 대조 시료가 세포생존에 미치는 영향력을 평가하기 위해 하기와 같은 MTT(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide) 분석을 수행하였다. MTT 분석은 탈수소 효소작용에 의하여 노란색의 수용성 기질인 MTT tetrazolium을 청자색을 띄는 비수용성의 MTT formazan으로 환원시키는 미토콘드리아의 능력을 이용하는 검사법으로, MTT formazan의 흡광도를 측정하며, 측정된 흡광도는 살아있고 대사가 왕성한 세포의 농도를 반영하는 것으로 잘 알려져 있다.In order to evaluate the effect of the paprika fermentation sample and the control sample prepared in Preparation Example 1 on the cell survival as follows MTT (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyl-tetrazolium bromide) analysis was performed. The MTT assay is a test that takes advantage of the mitochondria's ability to reduce the yellow water-soluble substrate, MTT tetrazolium, to a blue-violet, water-insoluble MTT formazan by dehydrogenase activity. It is well known to reflect the concentration of vigorous cells.
구체적으로, Clonetics (San Diego, CA, USA)에서 입수한 인간 피부 섬유아세포를 10% fetal bovine serum (FBS)와 100 U/ml penicillin이 첨가되어있는 Dulbecco's Modified Eagle's Medium (DMEM, Sigma co., St. Louis, MO, USA)에서 37℃, 5% CO2 조건으로 배양하였다. Specifically, human dermal fibroblasts obtained from Clonetics (San Diego, CA, USA) were added Dulbecco's Modified Eagle's Medium (DMEM, Sigma co., St.) containing 10% fetal bovine serum (FBS) and 100 U / ml penicillin. Louis, MO, USA) was incubated at 37 ℃, 5% CO 2 conditions.
얻어진 인간 피부 섬유아세포를 104 cells/well 밀도로 96 웰 플레이트(well plate)의 각 웰(well)에 분주하고 분화과정에서 1, 10, 20 ㎍/㎖ 농도로 준비예 1의 파프리카 발효 시료(FSc) 및 대조 시료(C)를 처리한 다음 48시간 후에 MTT(1 mg/ml PBS) 용액에서 4시간 동안 유지하였다. 이후 0.04 N HCl/isopropanol을 이용하여 용해시킨 후 분광 광도계(ELISA Reader, Bio-Rad, USA)를 이용하여 570 nm에서 흡광도를 측정하였다.The obtained human dermal fibroblasts were dispensed into each well of a 96 well plate at a density of 10 4 cells / well, and the paprika fermentation sample of Preparation Example 1 at concentrations of 1, 10 and 20 µg / ml during differentiation. FSc) and control sample (C) were treated and then maintained for 4 hours in MTT (1 mg / ml PBS) solution after 48 hours. After dissolving using 0.04 N HCl / isopropanol, the absorbance was measured at 570 nm using a spectrophotometer (ELISA Reader, Bio-Rad, USA).
그 결과가 도 1에 나타나 있다. 도 1에 나타난 바와 같이, 파프리카 대조 시료의 경우, 20 ㎍/㎖에서 독성이 있는 것으로 관찰되었으나, 본 발명의 파프리카 발효 시료의 경우에는 세포독성이 없고 안전한 것으로 나타났다.
The results are shown in Figure 1; As shown in FIG. 1 , the paprika control sample was observed to be toxic at 20 μg / ml, but the paprika fermentation sample of the present invention was found to be cytotoxic and safe.
<< 시험예Test Example 2> 2> 리폭시게나제Lipoxygenase 저해 효능 시험 Inhibitory efficacy test
리폭시게나제(lipoxygenase)는 각종 염증 및 알러지성 질환의 생합성 반응에 관여하는 효소로서, 리폭시게나제의 저해 정도평가는 화장품 관련 산업에서 피부 염증 감소 정도를 알아보기 위해 일반적으로 사용되는 방법이다 (Advances in Biological Research 2(3-4):56-59 (2008)). 이에 본 시험예에서는 본 발명의 파프리카 발효물에 의한 리폭시게나제의 저해 정도를 평가하였다. Lipoxygenase is an enzyme involved in the biosynthetic response of various inflammatory and allergic diseases. The evaluation of inhibition of lipoxygenase is a commonly used method to determine the extent of skin inflammation reduction in the cosmetics industry (Advances). in Biological Research 2 (3-4): 56-59 (2008)). In this test example, the degree of inhibition of lipoxygenase by the paprika fermentation product of the present invention was evaluated.
구체적으로, 준비예 1에서 제조한 파프리카 발효 시료(FSc) 및 파프리카 대조 시료(C)를 정제수에 1, 5, 10, 30 ㎎/㎖ 농도로 용해시켰다. 각각의 시료에 900 ㎖ borate buffer(0.2M, pH 9), 2 ㎖ linoleic acid (0.6 mM), 및 100 ㎖ 리폭시게나제(lipoxygenase)(20,000 U/㎖)를 함유한 용액을 상온에서 5분간 반응시킨 후 흡광도의 변화를 234 nm에서 측정하였다. 이때 정제수의 효소 활성을 함께 측정하여 상대적인 저해율로 시료의 리폭시게나제 저해 정도를 평가하였다. 양성 대조군(Control)으로는 항염증에 효과가 있는 인도메타신(indomethacin)을 20 ㎎/㎖로 희석하여 사용하였다.Specifically, the paprika fermentation sample (FSc) and paprika control sample (C) prepared in Preparation Example 1 were dissolved in purified water at a concentration of 1, 5, 10, 30 mg / ml. Each sample contains 900 ml borate buffer (0.2M, pH 9), 2 ml linoleic acid (0.6 mM), and 100 ml lipoxygenase (20,000 U / ml) at room temperature for 5 minutes. After the change in absorbance was measured at 234 nm. At this time, the enzyme activity of the purified water was measured to evaluate the degree of inhibition of lipoxygenase in the sample at a relative inhibition rate. As a positive control (Control), indomethacin (indomethacin) effective in anti-inflammatory was used diluted to 20 mg / ㎖.
그 결과는 도 2에 나타나 있다. 도 2에 나타낸 바와 같이, 본 발명에 따른 파프리카 발효 시료는 파프리카 대조 시료에 비해 리폭시게나제 저해 효능이 우수한 것으로 나타났다. 특히, 파프리카 발효 시료를 30 ㎎/㎖의 농도로 처리한 경우에는 인도메타신에 필적하는 높은 리폭시게나제 저해 효능을 나타내었다.
The results are given in Fig. As shown in Figure 2 , the paprika fermentation sample according to the present invention was shown to be superior to the lipoxygenase inhibitory effect compared to the paprika control sample. In particular, when paprika fermented samples were treated at a concentration of 30 mg / ml, they exhibited high lipoxygenase inhibitory effect comparable to indomethacin.
<< 시험예Test Example 3> 3> ICAMICAM -1 단백질 발현 억제 시험-1 protein expression inhibition test
피부 섬유아세포 내에서 ICAM-1(세포간 부착 분자-1; Intercellular adhesion molecule-1)의 증가는 대식세포 및 백혈구세포와 같은 염증과 관련되어 있는 세포들의 피부 내의 침윤현상을 일으킨다. ICAM-1은 자외선(UV) 조사시 발현정도가 증가하는 것으로 보고되고 있다 (John Wiley & Sons A/S, Experimental Dermatology, 19, e182-e190 (2010)). 이에, 본 시험예에서는 웨스턴 블랏 분석을 통해 자외선 B 조사에 의해서 유도된 ICAM-1 단백질에 대한 본 발명에 따른 파프리카 발효 시료의 발현 억제 정도를 평가하였다.Increasing ICAM-1 (Intercellular adhesion molecule-1) in dermal fibroblasts causes infiltration of the skin of cells involved in inflammation such as macrophages and white blood cells. ICAM-1 has been reported to increase the expression of ultraviolet (UV) irradiation (John Wiley & Sons A / S, Experimental Dermatology, 19, e182-e190 (2010)). In this test example, the degree of inhibition of expression of the paprika fermentation sample according to the present invention for the ICAM-1 protein induced by ultraviolet B irradiation was evaluated by Western blot analysis.
구체적으로, Clonetics (San Diego, CA, USA)에서 입수한 인간 피부 섬유아세포를 10% fetal bovine serum (FBS)와 100 U/ml penicillin이 첨가되어 있는 Dulbecco's Modified Eagle's Medium (DMEM, Sigma co., St. Louis, MO, USA)에서 37℃, 5% CO2 조건으로 배양하였다. Specifically, human dermal fibroblasts obtained from Clonetics (San Diego, CA, USA) were added Dulbecco's Modified Eagle's Medium (DMEM, Sigma co., St.) containing 10% fetal bovine serum (FBS) and 100 U / ml penicillin. Louis, MO, USA) was incubated at 37 ℃, 5% CO 2 conditions.
이후, 배지를 제거한 다음 phosphate buffered saline (PBS)로 세척하여 배지 내 serum 성분을 제거하고 Bio-sun (Vilber Lourmat, Marine, Cedex, France) 형광등을 이용하여 100 mJ/cm2 UV-B를 조사하였다.Then, the medium was removed and washed with phosphate buffered saline (PBS) to remove the serum components in the medium and irradiated with 100 mJ / cm 2 UV-B using a Bio-sun (Vilber Lourmat, Marine, Cedex, France) fluorescent lamp .
ICAM-1 단백질의 발현 정도를 확인하기 위해 웨스턴 블랏 분석을 수행하였다. 구체적으로, 자외선 처리된 인간 피부 섬유아세포에 준비예 1에서 제조한 파프리카 발효 시료 및 대조 시료를 농도별(1, 10, 20 ㎍/㎖)로 처리한 다음 150 ㎖ lysis buffer를 처리하여 세포 추출물을 준비하여 8% SDS-PAGE를 수행하였다. 비특이적인 결합을 방지하기 위하여 5% 탈지분유를 처리한 다음 ICAM-1 단백질의 일차항체(monoclonal rabbit anti-human antibody, Santa Cruz Biotech.)를 1000배 희석하여 교반하면서 반응시킨 다음, goat anti-rabbit horseradish peroxidase (1:10000, Jackson ImmunoReasearch Lab.)의 이차항체로 1시간 동안 반응시켰다. Nitrocellulose membrane에 있는 ICAM-1 단백질은 Supersignal West pico chemiluminescence (Pierce Biotech.)로 검출하여 X-ray 필름 (Konica Co.)으로 촬영하였다.Western blot analysis was performed to confirm the expression level of ICAM-1 protein. Specifically, the paprika fermentation sample and the control sample prepared in Preparation Example 1 were treated with UV-treated human skin fibroblasts by concentrations (1, 10, 20 ㎍ / ㎖) and then treated with 150 ml lysis buffer to extract the cell extracts. Prepared and performed 8% SDS-PAGE. To prevent nonspecific binding, 5% skim milk powder was treated, and then the primary antibody of the ICAM-1 protein (monoclonal rabbit anti-human antibody, Santa Cruz Biotech.) Was diluted 1000 times and reacted with stirring, followed by goat anti-rabbit. It was reacted with a secondary antibody of horseradish peroxidase (1: 10000, Jackson ImmunoReasearch Lab.) for 1 hour. ICAM-1 protein in the nitrocellulose membrane was detected by Supersignal West pico chemiluminescence (Pierce Biotech.) And photographed by X-ray film (Konica Co.).
그 결과는 도 3에 나타나 있다. 도 3에 나타낸 바와 같이, 자외선 B를 조사하지 않은 피부 섬유아세포에서는(No UV control), ICAM-1 단백질의 발현이 미약하였지만, 자외선 B를 조사하였을 때는(Control) ICAM-1 단백질의 발현이 현저히 증가하였다. 이러한 자외선 B를 조사한 피부 섬유아세포에 준비예 1의 파프리카 발효 시료와 파프리카 대조 시료를 각각 농도별(1, 10, 20 ㎍/㎖)로 처리한 결과, 본 발명의 파프리카 발효 시료로 처리된 세포군의 경우 ICAM-1 단백질의 발현이 크게 감소되었으며, 특히 10 ㎍/㎖ 이상의 농도에서는 UV를 처리하지 않은 경우와 유사한 수준의 ICAM-1 단백질 발현 수준을 나타내었다.
The results are given in Fig. As shown in FIG . 3, in the skin fibroblasts not irradiated with ultraviolet B (No UV control), the expression of ICAM-1 protein was weak, but when the ultraviolet B was irradiated (Control), the expression of ICAM-1 protein was remarkably increased. Increased. When the paprika fermented sample and Paprika control sample of Preparation Example 1 were treated at different concentrations (1, 10, 20 µg / ml) to the fibroblasts irradiated with ultraviolet B, the cell population treated with the paprika fermentation sample of the present invention was obtained. In the case of ICAM-1 protein expression was greatly reduced, especially at concentrations of 10 μg / ㎖ or more showed a similar level of ICAM-1 protein expression level than that without UV treatment.
<< 시험예Test Example 4> 4> NFNF -- kBkB 단백질 발현 억제 시험 Protein expression inhibition test
NF-kB는, 염증반응이 일어나면 세포질에서 핵으로 이동하여 발현량이 증가한다. 이에 본 시험예에서는 본 발명의 파프리카 발효물에 의한 NF-kB의 발현 억제 정도를 평가하였다. NF-kB moves from the cytoplasm to the nucleus and increases in expression when an inflammatory reaction occurs. In this test example, the degree of inhibition of expression of NF-kB by the paprika fermentation product of the present invention was evaluated.
구체적으로, 시험예 3에서와 같이 UV에 노출된 피부 섬유아세포(30 만개 세포/60 mm dish 밀도)에 준비예 1에서 제조한 파프리카 발효 시료 및 대조 시료를 농도별(1, 10, 20 ㎍/㎖)로 처리하였다. 배양 처리된 세포에 150 ㎖ lysis buffer를 가하여 세포 추출물을 준비하여 10% SDS-PAGE를 수행하였다. 비특이적인 결합을 방지하기 위하여 5% 탈지유(skim milk)를 처리한 후, 마우스 일차 항체 NF-kB(Cell Signaling Technology Inc., Beverly, MA, USA)를 1000배 희석하여 교반하면서 반응시키고, goat anti-rabbit horseradish peroxidase (1:10000, Jackson ImmunoReasearch Lab., Jackson ImmunoResearch Lab., West Grove, PA, USA)의 이차항체로 1시간 동안 반응시켰다. Nitrocellulose membrane에 있는 PPAR gamma와 C/EBP alpha의 단백질은 Supersignal West pico chemiluminescence (Pierce Biotech., Rockford, IL, USA)로 검출하여 X-ray 필름 (Konica Co., Tokyo, Japan)으로 촬영하였다.Specifically, the paprika fermentation sample and the control sample prepared in Preparation Example 1 to the skin fibroblasts (300,000 cells / 60 mm dish density) exposed to UV as in Test Example 3 by concentration (1, 10, 20 ㎍ / Ml). 150 ml lysis buffer was added to the cultured cells to prepare cell extracts, followed by 10% SDS-PAGE. After treatment with 5% skim milk to prevent nonspecific binding, mouse primary antibody NF-kB (Cell Signaling Technology Inc., Beverly, MA, USA) was diluted 1000-fold and reacted with stirring, goat anti -rabbit horseradish peroxidase (1: 10000, Jackson ImmunoReasearch Lab., Jackson ImmunoResearch Lab., West Grove, PA, USA) was reacted for 1 hour. Proteins of PPAR gamma and C / EBP alpha in the nitrocellulose membrane were detected by Supersignal West pico chemiluminescence (Pierce Biotech., Rockford, IL, USA) and photographed by X-ray film (Konica Co., Tokyo, Japan).
그 결과는 도 4에 나타나 있다. 도 4에 나타낸 바와 같이, 자외선 B를 조사하지 않은 피부 섬유아세포(No UV control)에서는 NF-kB 단백질이 거의 발현되지 않았으나, 자외선 B를 조사하였을 때(Control)는 NF-kB 단백질의 발현이 현저히 증가하였다. 이러한 자외선 B를 조사한 피부 섬유아세포에 본 발명에 따른 파프리카 발효 시료를 처리한 결과, NF-kB 단백질의 발현이 크게 감소되었으며, 특히 10 ㎍/㎖ 이상의 농도에서는 UV를 처리하지 않은 경우와 유사한 수준의 NF-kB 단백질 발현 수준을 나타내었다.
The results are given in Fig. As shown in FIG . 4 , the NF-kB protein was hardly expressed in the skin fibroblasts (No UV control) which did not irradiate ultraviolet B. However, when the ultraviolet B was irradiated (Control), the expression of the NF-kB protein was remarkably increased. Increased. As a result of treating the paprika fermentation sample according to the present invention to the skin fibroblasts irradiated with ultraviolet B, the expression of NF-kB protein was greatly reduced, especially at a concentration of 10 μg / ml or more, similar to that without UV treatment. NF-kB protein expression levels are shown.
이러한 결과는 본 발명에 따른 파프리카 발효물을 함유한 조성물이 피부 염증 완화에 매우 효과적임을 보여준다.
These results show that the composition containing the paprika fermentation product according to the present invention is very effective in alleviating skin inflammation.
<제조예 1> 영양화장수 (밀크 스킨로션)<Production Example 1> Nourishing Cream (Milk Skin Lotion)
통상의 방법에 따라 하기 표 1의 조성으로 영양 화장수를 제조하였다.The nutritional lotion was prepared by the composition of Table 1 according to a conventional method.
<제조예 2> 영양크림Preparation Example 2 Nutrition Cream
통상의 방법에 따라 하기 표 2의 조성으로 영양크림을 제조하였다.Nutritional cream was prepared in the composition of Table 2 according to a conventional method.
<< 제조예Manufacturing example 3> 팩 3> pack
통상의 방법에 따라 하기 표 3의 조성으로 팩을 제조하였다.According to a conventional method, a pack was prepared with the composition shown in Table 3 below.
Claims (5)
Paprika extract was inoculated with Saccharomyces cerevisiae MAB Y1 (Accession No .: KCTC 11386BP), fermented at 30 to 37 ° C. for 24 to 72 hours, and then ethanol was added at 100 to 121 ° C. Cosmetic composition for improving skin inflammation comprising paprika fermented product extracted for 15 to 30 minutes as an active ingredient.
상기 파프리카 추출액은 파프리카에 증류수를 가하여 100 내지 121℃에서 15 내지 30분 동안 열수 추출한 것임을 특징으로 하는 피부 염증 개선용 화장료 조성물.
The method of claim 1,
The paprika extract is a skin composition for improving skin inflammation, characterized in that the hydrothermal extraction for 15 to 30 minutes at 100 to 121 ℃ by adding distilled water to paprika.
상기 파프리카 발효물은 엔에프케이비(NF-kB), 리폭시게나제 및 세포간 부착인자-1(ICAM-1) 중에서 하나 이상을 억제하여서 염증 증상을 개선하는 것을 특징으로 하는 피부 염증 개선용 화장료 조성물.
The method of claim 1,
The paprika ferment is a cosmetic composition for improving skin inflammation, characterized by improving inflammation symptoms by inhibiting one or more of NF-kB, lipoxygenase and intercellular adhesion factor-1 (ICAM-1). .
상기 화장료 조성물은 유연화장수, 영양화장수, 영양로션, 마사지 크림, 보습 크림, 영양 크림, 팩, 젤, 바디 로션, 바디 크림, 바디 오일, 바디 에센스, 샴푸, 바디클렌저, 입용제 및 피부 점착 타입 화장료로 이루어진 군에서 선택된 어느 하나의 제형으로 형성되는 것을 특징으로 하는 피부 염증 개선용 화장료 조성물.
The method of claim 1,
The cosmetic composition is a flexible cosmetics, nourishing cosmetics, nourishing lotion, massage cream, moisturizing cream, nutrition cream, pack, gel, body lotion, body cream, body oil, body essence, shampoo, body cleanser, preparation and skin adhesive type cosmetic Cosmetic composition for improving skin inflammation, characterized in that formed in any one formulation selected from the group consisting of.
상기 화장료 조성물은 상기 파프리카 발효물이 조성물 총 중량을 기준으로 0.1 내지 2 중량%로 함유되는 것을 특징으로 하는 피부 염증 개선용 화장료 조성물.The method of claim 1,
The cosmetic composition is a cosmetic composition for improving skin inflammation, characterized in that the paprika fermented product is contained in 0.1 to 2% by weight based on the total weight of the composition.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100098353A KR101244101B1 (en) | 2010-10-08 | 2010-10-08 | Cosmetic composition for improving skin inflammation and including a fermented product of paprika as an effective ingredient |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100098353A KR101244101B1 (en) | 2010-10-08 | 2010-10-08 | Cosmetic composition for improving skin inflammation and including a fermented product of paprika as an effective ingredient |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20120036596A KR20120036596A (en) | 2012-04-18 |
KR101244101B1 true KR101244101B1 (en) | 2013-03-18 |
Family
ID=46138158
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020100098353A Expired - Fee Related KR101244101B1 (en) | 2010-10-08 | 2010-10-08 | Cosmetic composition for improving skin inflammation and including a fermented product of paprika as an effective ingredient |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101244101B1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101939918B1 (en) * | 2017-09-08 | 2019-01-17 | 신홍식 | Fermentation method of lactic acid bacteria using paprika and its use |
KR102147106B1 (en) | 2018-11-23 | 2020-08-24 | (주)엠앤씨생명과학 | Cosmetic Composition Containing Paprika And Process For Preparation Of The Same |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7235270B2 (en) * | 2003-03-10 | 2007-06-26 | Mayeux Jerry V | Pain balm |
WO2008052183A2 (en) * | 2006-10-27 | 2008-05-02 | Bmb Patent Holding Corporation | Therapeutic compositions and methods of treatment with capsianoside-type compounds |
KR20090123458A (en) * | 2008-05-28 | 2009-12-02 | 주식회사 엘씨에스바이오텍 | Fermentation method of natural plant material or herbal medicine, fermented product prepared by the above method and cosmetic composition, food composition and pharmaceutical composition containing same |
KR20100040715A (en) * | 2010-03-31 | 2010-04-20 | 대한민국(관리부서:국세청기술연구소장) | Method for preparing fermented alcoholic drink using paprika |
-
2010
- 2010-10-08 KR KR1020100098353A patent/KR101244101B1/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7235270B2 (en) * | 2003-03-10 | 2007-06-26 | Mayeux Jerry V | Pain balm |
WO2008052183A2 (en) * | 2006-10-27 | 2008-05-02 | Bmb Patent Holding Corporation | Therapeutic compositions and methods of treatment with capsianoside-type compounds |
KR20090123458A (en) * | 2008-05-28 | 2009-12-02 | 주식회사 엘씨에스바이오텍 | Fermentation method of natural plant material or herbal medicine, fermented product prepared by the above method and cosmetic composition, food composition and pharmaceutical composition containing same |
KR20100040715A (en) * | 2010-03-31 | 2010-04-20 | 대한민국(관리부서:국세청기술연구소장) | Method for preparing fermented alcoholic drink using paprika |
Also Published As
Publication number | Publication date |
---|---|
KR20120036596A (en) | 2012-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100847104B1 (en) | Atopic dermatitis remedy composition | |
KR102119825B1 (en) | A cosmetic composition for maintaining the balance of microbiom in the skin comprising brown rice, grean tea and dandelion fermentation extracts and methode thereof | |
KR101523631B1 (en) | A composition for anti-inflammation | |
KR102349188B1 (en) | Cosmetic composition for improving skin troubles due to fine dust | |
KR101716106B1 (en) | Seaweed mixed fermentation with an anti-inflammatory, anti-allergic and atopic skin improvement, a preparation method thereof and a cosmetic composition of the same | |
KR102125316B1 (en) | cosmetic composition for anti-irritation and skin soothing using Lactobacillus pentosus J2K-185strain | |
KR101930342B1 (en) | A cosmetic composition | |
KR101814498B1 (en) | Cosmetic Composition Containing the Mixed Extract of Eucalyptus Globulus Leaf and Trifolium Pratense Leaf | |
KR20220120948A (en) | Cosmetic composition for improving melasma, freckles, whitenings and wrinkle comprising extract of fermented chestnut inner shell, angelica dahurica, portulace oleracea, armeniacae and mori dadicis cortex and preparation method thereof | |
KR101908976B1 (en) | A cosmetic composition containing lactobacillus-fermented extract for improving atopic dermatitis | |
KR102016640B1 (en) | Composition containing extract using process of herbal medicine | |
KR20170092293A (en) | Cosmetic Composition Containing Fermented Extract from Lycium Chinense and Manufacturing Method Thereof | |
KR101960810B1 (en) | Cosmetic Composition Containing the Mixed Extract of Black Currant Fruit and Aronia Melanocarpa Fruit | |
KR101554999B1 (en) | A composition for whitening skin | |
KR101244101B1 (en) | Cosmetic composition for improving skin inflammation and including a fermented product of paprika as an effective ingredient | |
KR101789689B1 (en) | Cosmetic composition for improving atopic skin comprising extract Curcuma longa Linne leaf | |
KR102101949B1 (en) | A skin-care agent or cosmetics containig Antrodia camphorata fruit body extract or Antrodia camphorata mycelium extract | |
KR20130019186A (en) | Skin care preparations for whitening, anxi-oxidation or anti-biotics with fermented extract of lycium chinensis miller | |
KR101790185B1 (en) | Cosmetic composition containing extracting fraction of fermented beans as an active ingredient | |
KR102652401B1 (en) | Cosmetic composition comprising a double ferment of Kunzea ericoides extract | |
KR102139471B1 (en) | Fermented composition of ice plant and collagen for anti-aging and anti-wrinkle, method for preparing the same and cosmetic composition comprising the same | |
KR101970628B1 (en) | Cosmetic Composition Containing Extracts of Blackberry and Cranberry | |
KR102093879B1 (en) | The cosmetic composition containing root extract of Adenophora stricta for improving skin wrinkle | |
KR20160049790A (en) | Cosmetic composition comprising the extract of Ensete lasiocarpum as active ingredient | |
KR102421800B1 (en) | Composition comprising fermented extract of Halophilic microorganism |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20101008 |
|
PA0201 | Request for examination | ||
N231 | Notification of change of applicant | ||
PN2301 | Change of applicant |
Patent event date: 20120223 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20120530 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20130228 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20130308 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20130308 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
FPAY | Annual fee payment |
Payment date: 20151210 Year of fee payment: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20151210 Start annual number: 4 End annual number: 4 |
|
FPAY | Annual fee payment |
Payment date: 20170306 Year of fee payment: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20170306 Start annual number: 5 End annual number: 5 |
|
FPAY | Annual fee payment |
Payment date: 20200106 Year of fee payment: 8 |
|
PR1001 | Payment of annual fee |
Payment date: 20200106 Start annual number: 8 End annual number: 8 |
|
PR1001 | Payment of annual fee |
Payment date: 20210608 Start annual number: 9 End annual number: 9 |
|
PC1903 | Unpaid annual fee |
Termination category: Default of registration fee Termination date: 20221219 |